Brookline Capital Markets Starts Progenics Pharmaceuticals (PGNX) at Buy Citing Favorable Risk/Reward

March 20, 2018 10:58 AM

Brookline Capital Markets initiates coverage on Progenics Pharmaceuticals (NASDAQ: PGNX) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found